Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 8 min ago
Peer-reviewedCC BYeLife

Lenacapavir-induced lattice hyperstabilization is central to HIV-1 capsid failure at the nuclear pore complex and in the cytoplasm

  1. 1Department of Chemistry, Chicago Center for Theoretical Chemistry, Institute for Biophysical Dynamics, and James Franck Institute, The University of Chicago, Chicago, IL 60637
  2. 2Viral Mutation Section, HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, MD 21702

Abstract

Lenacapavir (LEN) is the first HIV-1 capsid inhibitor approved for clinical use. It inhibits multiple steps of the viral life cycle; however, the molecular details of the effect of LEN on capsid structure and the mechanistic steps of the inhibition are not understood. Recent studies show that intact cone-shaped capsids and capsids with LEN-induced breaks can dock at nuclear pore complexes (NPC), but only intact capsids enter the nucleus. In this work, we combined large-scale coarse-grained molecular dynamics simulations and live-cell imaging to investigate the stepwise mechanism of docking of LEN-treated capsids into the NPC. Capsids bound to substoichiometric concentrations of LEN can reach the NPC central channel. As the capsid advances to the nuclear end, lattice defects are formed at the pentamer-hexamer interface - primarily at the narrower end - leading to pentamer dissociation. Dissociation of pentamers is detrimental to capsid integrity, leading to both rupture of the narrow end and destabilization of the hexamer-hexamer interface. Structural analysis of LEN-capsid complexes in our simulations demonstrates heterogeneous hyperstabilization and loss of the essential pliability of the capsid protein lattice. Live-cell imaging of HIV-1 cores labeled with two different fluorescent markers showed that LEN-treated ruptured capsids were docked at the NPC but were not imported into the nucleus. We conclude that LEN contributes to the loss of capsid elasticity and integrity, inhibiting HIV-1 nuclear entry and replication. Our findings demonstrate that altering capsid material properties can be an effective strategy for designing antiviral drugs that disrupt viral core nuclear entry.

Related

  1. FapA extends the flagellar cage-dependent network into the cytoplasm to control surface-associated behaviors in Helicobacter pylori
    J. N. C. Fong, C. D. Witt, E. H. L. Huang +5
    bioRxivPreprintAll rights reservedFull textMicrobiologybioRxiv
  2. Dynamic microtubules drive yolk-cytoplasm segregation in the syncytial Drosophila embryo
    S. Thukral, P. Dey, B. Kaity +6
    bioRxivPreprintCC BY-NC-NDFull textDevelopmental biologybioRxiv
  3. Central and peripheral changes in oxygenation and temperatures induced by intravenous nicotine in freely moving male rats
    Ali Arce, Feonil Limiac, Eugene A. Kiyatkin
    Brain researchPeer-reviewedLicence not statedFull textNeurosciencePMC
  4. Central platelet-rich plasma administration promotes weight loss in diet-induced obese mice
    X. Yang, X. Hu, X. Yang +6
    bioRxivPreprintAll rights reservedFull textNeurosciencebioRxiv
  5. Lenacapavir allosterically remodels the HIV-1 capsid
    Nayara F. B. dos Santos, Jacob A. Lewis, Mason Hansen +5
    Science AdvancesPeer-reviewedCC BY-NCFull text8 citedMicrobiologyOpenAlex
BibTeX
@article{hudait2026lenacapavirinduced,
  title = {{Lenacapavir-induced lattice hyperstabilization is central to HIV-1 capsid failure at the nuclear pore complex and in the cytoplasm}},
  author = {Arpa Hudait and Ryan C. Burdick and Ellie K Bare and Vinay K. Pathak and Gregory A. Voth},
  journal = {eLife},
  year = {2026},
  month = jul,
  doi = {10.7554/elife.109282.4},
  url = {https://doi.org/10.7554/elife.109282.4},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Lenacapavir-induced lattice hyperstabilization is central to HIV-1 capsid failure at the nuclear pore complex and in the cytoplasm
AU  - Arpa Hudait
AU  - Ryan C. Burdick
AU  - Ellie K Bare
AU  - Vinay K. Pathak
AU  - Gregory A. Voth
PY  - 2026
DA  - 2026/07/08
JO  - eLife
DO  - 10.7554/elife.109282.4
UR  - https://doi.org/10.7554/elife.109282.4
AB  - Lenacapavir (LEN) is the first HIV-1 capsid inhibitor approved for clinical use. It inhibits multiple steps of the viral life cycle; however, the molecular details of the effect of LEN on capsid structure and the mechanistic steps of the inhibition are not understood. Recent studies show that intact cone-shaped capsids and capsids with LEN-induced breaks can dock at nuclear pore complexes (NPC), but only intact capsids enter the nucleus. In this work, we combined large-scale coarse-grained molecular dynamics simulations and live-cell imaging to investigate the stepwise mechanism of docking of LEN-treated capsids into the NPC. Capsids bound to substoichiometric concentrations of LEN can reach the NPC central channel. As the capsid advances to the nuclear end, lattice defects are formed at the pentamer-hexamer interface - primarily at the narrower end - leading to pentamer dissociation. Dissociation of pentamers is detrimental to capsid integrity, leading to both rupture of the narrow end and destabilization of the hexamer-hexamer interface. Structural analysis of LEN-capsid complexes in our simulations demonstrates heterogeneous hyperstabilization and loss of the essential pliability of the capsid protein lattice. Live-cell imaging of HIV-1 cores labeled with two different fluorescent markers showed that LEN-treated ruptured capsids were docked at the NPC but were not imported into the nucleus. We conclude that LEN contributes to the loss of capsid elasticity and integrity, inhibiting HIV-1 nuclear entry and replication. Our findings demonstrate that altering capsid material properties can be an effective strategy for designing antiviral drugs that disrupt viral core nuclear entry.
SN  - 2050-084X
ER  -